Discover open access scientific publications

Search, annotate, share and cite publications

Publications by R. Nuñez

P1.12-20 Overall Survival With Lurbinectedin Plus Doxorubicin in Relapsed SCLC. Results From an Expansion Cohort of a Phase Ib Trial

Journal of Thoracic Oncology

English

Week 4 Response Predicts Sustained Virological Response to All-Oral Direct-Acting Antiviral-Based Therapy in Cirrhotic Patients With Hepatitis C Virus Genotype 3 Infection

Clinical Microbiology and Infection

English

Related publications

Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin With Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma

English

P1.12-21 Developing a Real-World 3L Comparator to CheckMate 032: Overall Survival (OS) in Patients With Small Cell Lung Cancer (SCLC)

Journal of Thoracic Oncology

English

P1.12-11 2010 – 2015 Extensive Stage SCLC Diagnoses in a Canadian Institution: Baseline Characteristics That Impact on the Overall Survival

Journal of Thoracic Oncology

English

Therapy With Bortezomib Plus Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma: Final Results of a Phase II Trial (CALGB 50501)

Leukemia and Lymphoma

English

MA15.02 Long-Term Safety and Clinical Activity Results From a Phase Ib Study of Erlotinib Plus Atezolizumab in Advanced NSCLC

Journal of Thoracic Oncology

English

Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma

Journal of Clinical Oncology

English

Gemcitabine Plus Liposomal Doxorubicin for Relapsed Refractory T-Cell Lymphomas

Hematological Oncology

English

OA13.03 Anlotinib as Third-Line or Further-Line Treatment in Relapsed SCLC: A Multicentre, Randomized, Double-Blind Phase 2 Trial

Journal of Thoracic Oncology

English

P1.12-15 Distinctive Clinical Characteristics of SCLC in Never-Smokers

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by R. Nuñez

P1.12-20 Overall Survival With Lurbinectedin Plus Doxorubicin in Relapsed SCLC. Results From an Expansion Cohort of a Phase Ib Trial

Week 4 Response Predicts Sustained Virological Response to All-Oral Direct-Acting Antiviral-Based Therapy in Cirrhotic Patients With Hepatitis C Virus Genotype 3 Infection

Related publications

Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin With Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma

P1.12-21 Developing a Real-World 3L Comparator to CheckMate 032: Overall Survival (OS) in Patients With Small Cell Lung Cancer (SCLC)

P1.12-11 2010 – 2015 Extensive Stage SCLC Diagnoses in a Canadian Institution: Baseline Characteristics That Impact on the Overall Survival

Therapy With Bortezomib Plus Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma: Final Results of a Phase II Trial (CALGB 50501)

MA15.02 Long-Term Safety and Clinical Activity Results From a Phase Ib Study of Erlotinib Plus Atezolizumab in Advanced NSCLC

Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma

Gemcitabine Plus Liposomal Doxorubicin for Relapsed Refractory T-Cell Lymphomas

OA13.03 Anlotinib as Third-Line or Further-Line Treatment in Relapsed SCLC: A Multicentre, Randomized, Double-Blind Phase 2 Trial

P1.12-15 Distinctive Clinical Characteristics of SCLC in Never-Smokers